Leukaemia - acute lymphoblastic leukaemia

The PBS subsidises blinatumomab, dasatinib, imatinib and ponatinib for patients with acute lymphoblastic leukaemia (ALL).

Patient eligibility

Treatment with blinatumomab can be subsidised through the PBS under the National Health Act 1953, Efficient Funding of Chemotherapy – Section 100 Arrangements, for a patient with acute lymphoblastic leukaemia.

Treatment with dasatinib, imatinib and ponatinib can be subsidised through the PBS under the National Health Act 1953, Section 85 for patients with acute lymphoblastic leukaemia.

Patients must be eligible for the PBS and meet the relevant restriction criteria. 

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing blinatumomab, dasatinib, imatinib and ponatinib.

Applications

Initial treatment

Blintumomab

Make all initial (induction) applications for authority approval to prescribe blinatumomab for the treatment of ALL in writing and:

All applications must include the completed:

You can make an application for a balance of supply by calling the PBS Complex Drugs Program enquiry line.

Patients must not receive more than 2 treatment cycles under the Initial (Induction) and Initial (Induction) - balance of supply restrictions.

Dasatinib

Make all initial applications for authority approval to prescribe dasatinib for the treatment of acute lymphoblastic leukaemia in writing and:

All applications must include the completed:

Imatinib

Make all initial applications for authority approval to prescribe imatinib for the treatment of ALL in writing and:

All applications must include the completed:

Ponatinib

Make all initial applications for authority approval to prescribe ponatinib for the treatment of ALL in writing and:

All applications must include the completed:

Initial grandfather treatment

Blintumomab

For patients who received non PBS subsidised blinatumomab treatment for ALL before 1 May 2017, make all initial grandfather applications in writing and:

All applications must include the completed:

A patient qualifies for PBS subsidised blintumomab under the grandfather restriction once only.

Ponatinib

For patients who received non PBS subsidised ponatinib treatment for ALL before 1 September 2018, make all initial grandfather applications in writing and:

Make all initial applications for authority approval to prescribe ponatinib for the treatment of ALL in writing and:

All applications must include a completed:

A patient may qualify for PBS subsidised ponatinib under the grandfather restriction once only.

Continuing treatment

To make continuing applications for the treatment of ALL, call the PBS Complex Drugs Programs enquiry line.

Continuing blinatumomab treatment must not exceed 3 treatment cycles in a lifetime. Continuing imatinib treatment must not exceed 24 months in a lifetime.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 3 September 2018